Denmark
Denmark

Time filter

Source Type

Hoersholm; November 3rd 2016 - Medical Prognosis Institute A/S (MPI) announced today that, as a consequence of an exercise of warrants in an ongoing warrant program as described in the company description published June 21st  2016 the share capital has been increased by nominal DKK 2,000. The increase is affected without any pre-emption rights for the existing shareholders of the company or others. The shares are subscribed in cash at a price of DKK 0.52 per share of nominally DKK 0,05. Proceeds to the company are DKK 20,800. The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares shall give rights to dividends and other rights in relation to the company as of subscription, i.e. inter alia full rights to dividends for the financial year 2016. MPI's current share capital amounts to DKK 1,166,115 and will after the capital increase be DKK 1,168,115. The capital increase is expected to be finalized shortly. About MPI's multiple biomarker called Drug Response Predictor - DRP(TM) MPI's DRP(TM) is a tool for developing tumor-derived genetic signatures to predict which cancer patients are high likely to respond to a given anti-cancer product. The DRP(TM) has been tested in 37 trials, where 29 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients responded well to the treatment. The DRP(TM) platform has amongst others been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given   anti-cancer drug.  In addition to this, the individual genetic patterns of patients can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of patients with a high likelihood of response to the drug. DRP(TM) builds on comparison between sensitive and resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. The DRP(TM) is a Big Data tool based on messenger RNA. The DRP(TM) platform can be used in all cancer types, and has been patented for more than 60 anti-cancer drugs in the US. About MPI Medical Prognosis is a publicly traded international company specialized in improving cancer patients lives by developing Personalized Medicine using its unique DRP(TM) technology. MPI's exceptional opportunity to personalize cancer treatment - begins with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI's DRP(TM) tool has shown its ability to separate patients who benefit and who do not benefit from a specific cancer treatment. This has been shown in as many as 29 out of 37 trials, and covers more than 80 anti-cancer treatments in a wide range of cancer indications. MPI has built a significant large database with over 1,100 screened breast cancer patients and is building up a database in Multiple Myeloma to be followed by Prostate cancer in collaboration with oncologists and hematologists throughout Denmark. For further information, please contact: CEO, Peter Buhl Jensen, Adjunct Professor, MD, PhD                              Ulla Hald Buhl, IR & Communication E-mail: pbj@medical-prognosis.com                                                          E-mail: uhb@medical-prognosis.com Telephone: +45 21 60 89 22                                                                        Telephone +45 21 70 10 49 This information is information that Medical Prognosis Institute A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on November 3rd  2016.


News Article | November 4, 2016
Site: globenewswire.com

The Annual General Meeting of Chr. Hansen Holding A/S will take place on Tuesday 29 November 2016 at 4:00 pm CET at the Company’s premises Boege Allé 10-12, 2970 Hoersholm, Denmark subject to the attached notice setting out the complete wording of the proposals, which the Board of Directors intends to table at the General Meeting. For further information, please contact: Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The products include cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2015/16 financial year was EUR 949 million. The company has more than 2,700 dedicated employees in 30 countries and main production facilities in Denmark, France, USA and Germany. Chr. Hansen was founded in 1874 and is listed on Nasdaq Copenhagen. For further information, please visit www.chr-hansen.com.


Rask C.,Hoersholm | Lund L.,ALK Abello A S | Lund G.,Hoersholm | Heydenreich B.,Johannes Gutenberg University Mainz | And 4 more authors.
Clinical and Experimental Allergy | Year: 2012

Background: Subcutaneous specific immunotherapy (SCIT) has proven sustained clinical efficacy against allergy. The recommended regimen for SCIT is a gradual updosing over a period of weeks. Commonly, in commercial products for SCIT, the specific allergen is formulated with an adjuvant, most often in the form of aluminium hydroxide (AlOH). It has been shown that allergen-specific IgG antibodies are induced as a result of successful SIT. Objective: To investigate the possibility of optimizing the formulation of AlOH-based grass-pollen allergy vaccines for SCIT in a way that allows for shorter updosing regimens while maintaining the immunogenicity of the vaccine. Methods: Mice were immunized with various concentrations of Phleum pratense (Phl p) allergen extract and AlOH or a fixed dilution of the maintenance doses of one conventional and one alternatively formulated vaccine. The kinetics of Phl p-specific IgG antibody responses in serum and spleen T cell responses were determined. Allergenicity, measured as the ability of the formulations to activate human basophils, was also determined. In addition, human T cell responses and the expression of dendritic cell surface markers after vaccine challenge in vitro were analysed. Results: Specific IgG antibody responses were shown to depend on the AlOH concentration, but not on the allergen concentrations. The immunogenicity of the conventional formulation and the alternative formulation was shown to be similar with regard to the in vivo-induced IgG and T cell responses. In contrast, the allergenicity of the alternative formulation was significantly reduced compared with the conventional formulation. Conclusion: The optimization of the formulation allows for administration of a lower dose of allergen while maintaining the immunogenicity of the product and at the same time reducing allergenicity. Clinical Relevance: This study indicates that the optimization of the allergen and the adjuvant formulation could benefit the safety/efficacy profile and allow for shorter updosing. © 2012 Blackwell Publishing Ltd.


Madsen T.,Hoersholm | Slothuus T.,Hoersholm | Petersen G.I.,Hoersholm | Rasmussen D.,Hoersholm
Tenside, Surfactants, Detergents | Year: 2011

Exposure and effect assessment including risk characterisation of enzymes used in household detergents were conducted. Predicted environmental concentrations were calculated by use of traditional methods and detailed transport and fate modelling. Predicted no effect concentrations were derived from the results of ecotoxicological studies conducted with subtilisin and other available information on the acute and chronic aquatic toxicity. Risk characterisation ratios were defined as the ratio between the predicted environmental concentration and the predicted no effect concentration. Risk characterisation ratios were calculated for fresh and marine water and were found to be between 0. 0002 and 0.06, i.e. all well below 1. This shows that under the given conditions, the use of enzymes in household detergents does not present a risk to the aquatic environment. © Carl Hanser Publisher.


Rasmussen D.,Hoersholm | Slothuus T.,Hoersholm | Petersen G.I.,Hoersholm | Madsen T.,Hoersholm
Tenside, Surfactants, Detergents | Year: 2011

Exposure and effect assessments including risk characterisation of the surfactants alcohol ethoxylates, alcohol ethoxysulphates and linear alkylbenzene sulphonates used in household detergents were conducted. Predicted environmental concentrations were calculated by use of traditional methods and detailed transport and fate modelling. Predicted no effect concentrations were derived from the available information on the acute and chronic aquatic toxicity. Risk characterisation ratios were defined as the ratio of the predicted environmental concentration to the predicted no effect concentration. Risk characterisation ratios were calculated for fresh water and marine water and were below 1. This indicates that based on the methods employed in this study the use of alcohol ethoxylates, alcohol ethoxysulphates and linear alkylbenzene sulphonate in household detergents does not appear to present a risk to the aquatic environment. © Carl Hanser Publisher, Munich.

Loading Hoersholm collaborators
Loading Hoersholm collaborators